| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $2.48B | +1.9% |
| Gross profit | $2.48B | — |
| Operating income | $0.38B | — |
| Net income | $0.32B | +32.8% |
| Gross margin | 100.0% | Net margin 12.9% |
| Segment | Revenue | Share |
|---|---|---|
| AVONEX | $0.16B | 6.6% |
| SKYCLARYS | $0.15B | 6.1% |
| BENEPALI | $0.12B | 4.9% |
| TECFIDERA | $0.11B | 4.4% |
| PLEGRIDY | $0.06B | 2.6% |
| LEQEMBICollaboration | $0.06B | 2.4% |
| Alzheimers Collaboration | $0.06B | 2.4% |
| ZURZUVAE | $0.06B | 2.2% |
| Other Products | $0.06B | 2.2% |
| IMRALDI | $0.05B | 2.0% |
| QALSODY | $0.03B | 1.3% |
| FLIXABI | $0.01B | 0.4% |
| Royalty | $0.01B | 0.4% |
| FAMPYRA | $0.00B | 0.0% |
| BYOOVIZ | $0.00B | 0.0% |
| TOFIDENCE | $0.00B | 0.0% |
| FUMADERMAnd ADUHELM | $0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| SG&A | $0.61B | 24.5% |
| Tax & other | $0.06B | 2.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BLK ・ BX ・ XYZ ・ BNY ・ BA ・ BKNG ・ BSX ・ BMY ・ AVGO ・ BR ・ BRO ・ BF.B
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies